In these 731 triple-positive patients analyzed, HER2-positive/hormone receptor-positive patients—when compared with HER2-positive/hormone receptor-negative patients—were slightly younger at the time of breast cancer diagnosis, had a smaller breast cancer tumor size and a lower rate of low primary tumor differentiation. Here, ERBB2 is linked to breast cancer.